Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (31-40 of 338) with videos related to

Pageof 34
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B Atkins
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B Atkins
The Lancet. Oncology|October 3, 2009
Resistance to targeted therapy in renal-cell carcinomaBrian I Rini, Michael B Atkins
Seminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B Atkins
Nature Reviews. Clinical Oncology|November 28, 2009
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?Toni K Choueiri, Michael B Atkins
Oncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B Atkins
Cancer|January 30, 2019
Choice of first-line therapy in metastatic melanomaGeoffrey T Gibney, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Rapid development of hypertension by sorafenib: toxicity or target?Benjamin D Humphreys, Michael B Atkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
More support for the judicious use of high-dose interleukin-2 in patients with advanced melanomaDavid F McDermott, Michael B Atkins
Pageof 34

Showing results (31-40 of 338) with videos related to

Sort By:
Pageof 34
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B Atkins
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B Atkins
The Lancet. Oncology|October 3, 2009
Resistance to targeted therapy in renal-cell carcinomaBrian I Rini, Michael B Atkins
Seminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B Atkins
Nature Reviews. Clinical Oncology|November 28, 2009
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?Toni K Choueiri, Michael B Atkins
Oncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B Atkins
Cancer|January 30, 2019
Choice of first-line therapy in metastatic melanomaGeoffrey T Gibney, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Rapid development of hypertension by sorafenib: toxicity or target?Benjamin D Humphreys, Michael B Atkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
More support for the judicious use of high-dose interleukin-2 in patients with advanced melanomaDavid F McDermott, Michael B Atkins
Pageof 34